KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Change in Accured Expenses (2020 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Change in Accured Expenses for 6 consecutive years, with $13.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 24.88% year-over-year to $13.1 million, compared with a TTM value of -$4.7 million through Dec 2025, down 134.92%, and an annual FY2025 reading of -$4.7 million, down 134.92% over the prior year.
  • Change in Accured Expenses was $13.1 million for Q4 2025 at Aurinia Pharmaceuticals, up from -$641000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $17.5 million in Q4 2024 and bottomed at -$23.4 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $1.3 million, with a median of $539000.0 recorded in 2022.
  • The sharpest move saw Change in Accured Expenses tumbled 675.61% in 2021, then soared 5931.36% in 2022.
  • Year by year, Change in Accured Expenses stood at $2.9 million in 2021, then crashed by 78.95% to $616000.0 in 2022, then plummeted by 44.48% to $342000.0 in 2023, then soared by 5007.89% to $17.5 million in 2024, then decreased by 24.88% to $13.1 million in 2025.
  • Business Quant data shows Change in Accured Expenses for AUPH at $13.1 million in Q4 2025, -$641000.0 in Q3 2025, and $6.3 million in Q2 2025.